Practical Considerations and Strategies for Executing Adaptive Clinical Trials

Drug Information Journal

Volumn 46, Issue 2, 2012, Pages 160-174

  He, Weili ^a   Kuznetsova, Olga M ^a   Harmer, Mark ^b   Leahy, Cathy ^a   Anderson, Keaven ^a   Dossin, Nicole ^a   Li, Lina ^a   Bolognese, James ^a,c   Tymofyeyev, Yevgen ^d   Schindler, Jerald ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD   (United Kingdom)

^c Cytel Incorporated   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

adaptive designs; clinical supply; data monitoring committee; IVRS; modeling and simulation

Indexed keywords

ARTICLE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG USE; HUMAN; MODEL; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION;

EID: 84864798414     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512436580     Document Type: Article

References (52)

1. Dragalin V.Adaptive designs: terminology and classification.Drug Inf J. 2006;40:425-435.
2. Gallo P,Chuang-Stein C,Dragalin V,Gaydos B,Krams M,Pinheiro J.Executive summary of the PhRMA Working Group on Adaptive Designs in Clinical Drug Development.J Biopharm Stat. 2006;16:275-283.
3. Full white paper.Drug Inf J. 2006;40:421-484.
4. Special issue.Biomed J. 2006;4:491-737.
5. US Food and Drug Administration. Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed April 2011.
6. J Biopharm Stat. 2010:1083-1219.
7. Chow S.A note on special articles on adaptive clinical trial designs.J Biopharm Stat. 2010;20:088-1089.
8. Quinlan JA,Krams M.Implementing adaptive designs: logistical and operational considerations.Drug Inf J. 2006;40:437-444.
9. Gallo P.Confidentiality and trial integrity issues for adaptive designs.Drug Inf J. 2006;40:445-450.
10. Gaydo B,Anderson K,Berry D, et al.Good practices for adaptive clinical trials in pharmaceutical product development.Drug Inf J. 2009;43:539-556.
11. Gaydos B,Krams M,Perevozskaya I, et al.PhRMA Working Group on Adaptive Designs: adaptive dose-response studies.Drug Inf J. 2006;40:451-461.
12. Parke TAdaptive clinical trials in the real world. Paper presented at: Massachusetts Biotechnology Council; April 23, 2008; Cambridge, MA.
13. Youden WJ.Inadmissible random assignments.Technometrics. 1964;6:103-104.
14. Youden WJ.Randomization and experimentation.Technometrics. 1972;14:13-22.
15. Song C,Kuznetsova OM.Implementing constrained or balanced across-the-centers randomization with SAS v8 Procedure PLAN.PharmaSUG 2003 Proceedings. 2003;:473-479.
16. Kuznetsova O,Ivanova APharmaceutical Statistics Using SAS. Dmitrienko AChuang-Stein CD'Agostino R, ed. Cary, NC: SAS Press; 2006:.
17. Kuznetsova OMWiley Encyclopedia of Clinical Trials. D'Agostino RSullivan LMassaro J, ed. Hoboken, NJ: John Wiley &Sons, Inc; 2008:.
18. Kuznetsova OM,Tymofyeyev Y.Brick tunnel randomization for unequal allocation to two or more treatment groups.Stat Med. 2011;30:812-824.
19. Kuznetsova OM.Why Permutation is even more important in IVRS drug codes schedule generation than in patient randomization schedule generation.Control Clin Trials. 2001;22:69-71.
20. Lang M,Wood R,McEntegart D.Protecting the blind.Good Clinical Practice Journal. 2005;12:10-13.
21. Riege D,Tourtellotte E.Drug pooling: power and pitfalls.Applied Clinical Trials Online.
22. Byrom B,McEntegart DAdaptive Designs in Pharmaceutical/Clinical Development. Chow SC, ed. Boca Raton, FL: Chapman & Hall/CRC, Taylor and Francis; 2010:.
23. Morrissey M,McEntegart D,Lang M.Randomisation in double-blind multicentre trials with many treatments.Contemp Clin Trials. 2010;31:381-391.
24. McEntegart DWiley Encyclopedia of Clinical Trials. D'Agostino RSullivan LMassaro J, ed. Hoboken, NJ: John Wiley & Sons, Inc; 2008:.
25. Zelen M.The randomization and stratification of patients to clinical trials.J Chron Dis. 1974;27:365-375.
26. Kuznetsova OM,Tymofyeyev Y.Modified Zelen's approach randomization and covariate-adaptive allocation based on modified Zelen's approach in studies with unequal allocation.Contemp Clin Trials. 2011;32:962-972.
27. Frane JW.A method of biased coin randomization, its implementation, and its validation.Drug Inf J. 1998;32:423-432.
28. Rosenberger WF,Lachin JMRandomization in Clinical Trials. New York, NY: John Wiley & Sons; 2002:.
29. Therneau TM.How many stratification factors are "too many" to use in a randomization plan?.Control Clin Trials. 1993;14:98-108.
30. Taves D.Minimization: a new method of assigning subjects to treatment and control groups.Clin Pharmacol Ther. 1974;15:443-453.
31. Pocock SJ,Simon R.Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.Biometrics. 1975;31:103-115.
32. Heritier S,Gebski V,Pillai A.Dynamic balancing randomization in controlled clinical trials.Statist Med. 2005;24:3729-3741.
33. Signorini DF,Leung O,Simes RJ,Beller E,Gebski VJ.Dynamic balanced randomisation for clinical trials.Stat Med. 1993;12:2343-2350.
34. Scott NW,McPherson GC,Ramsay CR,Campbell MK.The method of minimization for allocation to clinical trials: a review.Control Clin Trials. 2002;23:662-674.
35. Nishi T,Takaishi A.An extended minimization method to assure similar means of continuous prognostic variable between treatment groups.Japan J Biometrics. 2003;24:43-55.
36. Kuznetsova OM,Tymofyeyev Y.Expansion of the modified Zelen's approach randomization and dynamic randomization with partial block supplies at the centers to unequal allocation.Contemp Clin Trials. 2011;32 (6): 962-972.
37. Proschan M,Brittain E,Kammerman L.Minimize the use of minimization with unequal allocation.Biometrics. 2011;67:1135-1141.
38. Han B,Enas NH,McEntegart D.Randomization by minimization for unbalanced treatment allocation.Stat Med. 2009;28:3329-3346.
39. Kuznetsova OM,Tymofyeyev Y.Preserving the allocation ratio at every allocation with biased coin randomization and minimization in studies with unequal allocation.Stat Med.
40. Rosenberger WF,Sverdlov O.Handling covariates in the design of clinical trials.Statist Sci. 2008;23:404-419.
41. Zhang L,Rosenberger WAdaptive Designs in Pharmaceutical/Clinical Development. Chow SC, ed. New York, NY: Chapman & Hall/CRC, Taylor and Francis; 2010:.
42. Waters S,Dowlman I,Drake K,Gamble L,Lang M,McEntegart D.Enhancing control of the medication supply chain in clinical trials managed by interactive voice response systems.Drug Inf J. 2010;44:727-740.
43. Downs M,Tucker K,Christ-Schmidt H,Wittes J.Some practical problems in implementing randomization.Clin Trials. 2010;7:235-245.
44. Anisimov VAlexandria, VA: American Statistical Association;.
45. Barnard K,Dent L,Cook A.A systematic review of models to predict recruitment to multicentre clinical trials.BMC Med Res Methodol. 2010;10:63.
46. Carter RE,Sonne SC,Brady KT.Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study.BMC Med Res Methodol. 2005;5:11.
47. Anisimov V,Fedorov V.Modelling, prediction, and adaptive adjustment of recruitment in multicenter trials.Stat Med. 2007;26:4958-4975.
48. Williford WO,Bingham SF,Weiss DG,Collins JF,Rains KT,Krol WF.The "constant intake rate" assumption in interim recruitment goal methodology for multicenter clinical trials.J Chron Dis. 1987;40:297-307.
49. Gajewski BJ,Simon SD,Carlson SE.Predicting accrual in clinical trials with Bayesian posterior predictive distributions.Stat Med. 2008;27:2328-2340.
50. Abbas I,Rovira J,Casanovas J.Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment.Contemp Clin Trials. 2007;28:220-231.
51. Haidich AB,Ioannidis JP.Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies.BMC Med Res Methodol. 2001;1:4.
52. Silva E. Implementing adaptive designs: Using technology to protect trial integrity, reduce operational bias, and build regulatory trust. Paper presented at the 2011 DIA Conference; June 23, 2011: Chicago, IL.